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Aim To analyze the genesis of hypertrophic cardiomyopa-
thy on a large cohort of patients from molecular genetics 
point of view and perform the functional analysis of the 3D 
molecular model of defective myosin-7 protein in silico.
Methods The study enrolled 153 patients with diagnosed 
hypertrophic cardiomyopathy from different parts of the 
Czech Republic. DNA samples were analyzed for mutations 
in exons 21 and 22 of the MYH7 gene, which have been as-
sociated with high mutation clustering. The 3D model of 
human myosin-7 was built using the x-ray structure of nu-
cleotide-free scallop myosin S1 as the structural template. 
We performed de novo structure prediction of mutant and 
wild type peptides spanning the 769-788 amino acids re-
gion of the myosin-7 protein.
Results The Arg870His and Asp778Val amino acid alterations 
were found in 2 unrelated patients with a severe form of 
hypertrophic cardiomyopathy. The Asp778Val variation was 
chosen for subsequent 3D molecular modeling in silico. 
The mutation of the Asp by Val not only changes the char-
acter of the interaction pattern with other amino acids or 
ions but Val, being a small hydrophobic amino acid, can 
also completely change the stability of the region.
Conclusion  Mutation  location  in  the  MYH7  gene  and 
changes in amino acid composition may have a crucial 
negative impact on the outcome of the disease in patients 
with hypertrophic cardiomyopathy. In addition, a mutation 
that changes the charge of the amino acid is more likely to 
affect protein function than a conservative mutation.
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Hypertrophic  cardiomyopathy  (HCM)  is  a  complex  in-
heritable cardiac disease that is highly clinically and ge-
netically heterogeneous. Leading macroscopical clinical 
features of HCM are left and/or right ventricular hyper-
trophy, which in most cases is asymmetric with the in-
volvement  of  the  intraventricular  septum  in  absence 
of other causes of hypertrophy (eg, valvar stenosis and 
hypertension). However, the symmetrical form of HCM 
accounts for over one third of cases and is character-
ized by concentric thickening of the left ventricle with a 
small ventricular cavity dimension (1). The prevalence of 
the HCM in the general population is 0.2% according to 
the echocardiographic criteria (2). From a genetic point 
of view, HCM is a congenital cardiac disease with auto-
somal dominant pattern of inheritance and incomplete 
penetrance (3). In some families, the onset of disease oc-
curs late in adulthood, the hypertrophy is minimal, and 
patients have a normal lifespan, while in other families 
the onset occurs very early and may lead to a massive 
hypertrophy  associated  with  severe  symptoms  and  a 
very short lifespan due to a sudden cardiac death (4-7). 
There are many risk factors linked with the worsening of 
HCM, such as diabetes mellitus, high levels of cholester-
ol, and a number of prothrombotic abnormalities. There-
fore, long term attention should be paid to the testing of 
new drugs that reduce the production of inflammatory 
aggregates/plaques. The correction of these aberrations 
may translate into the reduction of cardiovascular risk in 
patients with HCM (8,9).
HCM is mostly attributed to multiple mutations in ap-
proximately 16 genes that have been identified until now 
(10-12).  Mutations  associated  with  HCM  development 
have been found in genes that encode components of 
the thick filament proteins: myosin-7 and myosin-binding 
protein C and in genes that encode the components of 
the thin filament proteins: cardiac troponin T (13), cardiac 
troponin C, cardiac troponin I, and α-tropomyosin (14,15). 
MYH7, a gene encoding myosin-7 protein, was the first 
gene to be linked with HCM development (16). It is a large 
gene located on the chromosome 14q11.2–q13 in hu-
mans with 40 exons forming a transcript of 6027 bp. The 
size of myosin-7 is 1935 amino acids. The head region ex-
tends from exon 3 to part way through exon 21, the neck 
from part way through exon 21 to part way through exon 
25, and the tail from exon 25 to 40. The functional sites 
of myosin-7 are as follows: 1) ATP-binding domain (exons 
5-12), 2) actin-binding domain (exons 13-16), and 3) light 
chain-binding sites extends through exon 21 and 22 of 
the MYH7 gene.
The genetic part of the study focused on the mutation 
screening of the exons 21 and 22 of the MYH7 gene. The 
selected exons encode light chain-binding sites of the my-
osin-7 protein. High mutation clustering within this region 
was reported by many scientists (17). An identification of 
pathogenic mutation might be beneficial in the process 
of preclinical diagnosis and in genetic counseling. More 
mutations occur in the head and neck than in the tail of 
myosin-7. In the head region, 130 mutations have been re-
ported in association with HCM development (size of the 
region: 778 amino acids), 52 in the neck (289 amino acids), 
and 25 in the tail (868 amino acids). It is widely agreed that 
mutations in the head region of the MYH7 gene are more 
likely to lead to a severe form of HCM (18).
The diagnosis of HCM depends on the molecular identifi-
cation and analysis of the candidate genes and of the ab-
normal gene product (3,19). To be able to understand how 
mutations in different genes, especially those that encode 
for contractile proteins cause HCM, it would be necessary 
to understand the functional consequences of the muta-
tions at the molecular level (11). With the knowledge of the 
responsible genes and the ability to detect the underly-
ing genetic and proteomic defect, we will be able to de-
termine whether specific genotypes lead to different phe-
notypes (20-22).
The aim of this study was to analyze the HCM genesis from 
the molecular genetics point of view, perform a functional 
analysis of defective myosin-7 protein in silico, and investi-
gate specific mutations that change the charge of the ami-
no acids responsible for the HCM development.
MateRial and MethodS
Molecular genetic analysis of exons 21 and 22 of the 
MYh7 gene
A total of 153 patients from different parts of the Czech 
Republic were enrolled to this study. All of the collected 
samples were fully anonymous and were given voluntary 
during the period 2000-2003. Informed consent was ob-
tained from all study participants. The DNA bank of the De-
partment of Anthropology and Human Genetics, Faculty of 
Science, Charles University in Prague houses all the tested 
samples and all procedures were carried out in line with 
the institutional ethical guidelines. This cohort was di-
vided into two major subgroups: 1) patients with a spo-
radic form of HCM in whom HCM had been clinically 
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of HCM had been reported (n = 102), 2) patients with a fa-
milial HCM in whom positive HCM occurrence had been 
previously found in at least one of the family members – 
24 families with a familial form of HCM diagnosis had been 
identified to meet this criterion (n = 51).
DNA was extracted from peripheral blood leukocytes by 
phenol-chloroform  extraction.  Conditions  for  the  poly-
merase  chain  reaction  (PCR)  were  as  follows  for  exons 
21/22: 1.5 mM MgCl2/ 2 mM MgCl2; 10 × PCR Buffer (70 mM 
KCl, 14 mM Tris-HCl); 2 mM dNTPs; 0.20 U Taq (5U/µL) (Ta-
KaRa Bio, Inc., Shiga, Japan) and primers (each of total 10 
µM concentration). Total reaction volume was 10 µL and 
we used 1-10 ng of template DNA per reaction (quanti-
fied by spectrophotometry). PCR was performed for am-
plification of specific regions of the genomic DNA (PCR 
program: 30 cycles, 94°C/5 minutes, 60°C/30 seconds for 
exon 21, and 62°C/30 seconds for exon 22, 72°C/1 min-
ute, final extension 72°C/10 minutes, and 4°C hold). Oligo-
nucleotide primer sequences were as follows: for exon 21: 
5’- TAG GCT GTT ACC CTT CCT AAG GTA - 3’; 5’- GCC TCT 
GAC CCT GTG ACT GCA GTG - 3’ and exon 22: 5’- GGA CCT 
CAG GTA GGA AGG AGG CAG - 3’; 5’- TGT GCA GGG AGG 
TGC AGG GTT GTG - 3’.
All tested samples were analyzed by automatic dye termi-
nator cycle sequencing using genetic analyzer ABI Prism 
310 (Applied Biosystems, Foster City, CA, USA). DNA sam-
ples were analyzed for mutations in the nucleotide se-
quence of exons 21 and 22 of the MYH7 gene, which are 
associated with a high number of mutations.
homology model of human myosin-7
The 3D model of human myosin-7 was built using the x-
ray structure of nucleotide-free scallop myosin S1 (protein 
data bank accession code 1KK8) as the structural template. 
Based on global pair-wise alignment of the human (Uni-
prot id P12883) and scallop myosin (Uniprot id P24733) 
performed  by  EMBOSS  Pairwise  Alignment  Algorithms 
(The  European  Molecular  Biology  Open  Software  Suite, 
http://www.ebi.ac.uk/Tools/emboss/align/)  with  BLO-
SUM62 (blocks of amino acid substitution matrix), replace-
ment of the structurally conserved regions and rebuilding 
of the said variable regions was done with the homology 
module  of  molecular  operating  environment  program 
(Chemical Computing group Inc., Montreal, Canada). Root 
mean square deviation of the framework (Cα) was about 
2.4 Å in the energy optimized model of myosin-7 pro-
tein compared with scallop myosin. Only the region 
spanning amino acids 1 to 835 of the myosin-7 was mod-
eled because mutation in question – Asp778Val was present 
in this part of the structure.
Short peptides mapping the 769-788 amino acids 
region of myosin-7
We  performed  a  de  novo  structure  prediction  of  mu-
tant and wild type peptides spanning the 769-788 ami-
no acids region of myosin-7. The first peptide sequence 
contained the Asp amino acid at position 778 – LLGLL-
EEMRdERLSRIITRI, while the second peptide was Asp778Val 
mutant variant of the wild type myosin-7 fragment – LL-
GLLEEMRVERLSRIITRI.  We  used  the  web  based  predic-
tion PEP-FOLD server (peptide structure prediction serv-
er, http://bioserv.rpbs.univ-paris-diderot.fr/PEP-FOLD/) to 
obtain 3D models of the peptides (wild type and mutant 
variant). PEP-FOLD method is based on structural alpha-
bet and uses a greedy algorithm and a coarse-grained 
force field to predict a structure (23).
ReSultS
Two sequence alterations were found in 2 unrelated pa-
tients with the severe form of HCM. These 2 patients be-
long to the first subgroup of patients with the sporadic 
form of HCM in which no family history of the disease and 
sudden cardiac death was reported. The patient with the 
Arg870His substitution was 36 years old at the time of diag-
nosis with the left ventricular wall thickness of 28 mm and 
the left ventricular outflow tract gradient of 60 mm Hg. 
The patient with the Asp778Val mutation was 23 years old 
at the time of diagnosis with the left ventricular wall thick-
ness of 32 mm and the left ventricular outflow tract gradi-
ent of 90 mm Hg. The Arg870His (codon change: CGC>CaC; 
nucleotide position in the MYH7 gene: 14593) mutation 
was observed in the exon 22 of the MYH7 gene. The As-
p778Val (codon change: GaC>GtC; nucleotide position in 
the MYH7 gene: 14061) was reported for the first time in a 
European patient with HCM. This mutation was detected 
in the encoding sequence of exon 21 of the MYH7 gene 
(24).  Both  of  the  patients  had  chronic  atrial  fibrillation, 
chest pain, fatigue, and dyspnea. The patient with Asp778Val 
had had a few episodes of syncopes before the treatment. 
Drug treatment included the use of beta blockers and cal-
cium channel blockers.
The Asp778Val amino acid alteration was chosen for sub-
sequent molecular modeling, since we believe that it can 
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homology model of myosin-7 protein
A homology model of the myosin-7 N-terminal, motor do-
main, and 5 amino acids extended EF hand (the motif con-
taining helix-loop-helix structural domain found in a large 
family  of  calcium-binding  proteins)  binding  site  (1-779 
amino acids, 780-835 amino acids) was created using scal-
lop myosin as a template (PDB 1KK8). The full length align-
ment of both full sequences of length 1958 amino acids 
showed  relatively  good  agreement  to  build  a  homolo-
gy-based model. The identity of both chains was 55.8% 
(1092/1958) and the similarity was 74.6% (1460/1958). The 
homology-modeled part of myosin-7 (1-835 amino acids) 
provided almost the same identity (61.2%) and similarity 
(71.2%). Two structures of myosin-7 were obtained rep-
resenting two variants of the protein – the wild type and 
the Asp778Val mutant. There is no difference between these 
two models at general molecular level (Figure 1). Even the 
Asp778Val mutant shows the same helicity, spanning the 
761-830 amino acid region.
The model shows that the aspartic acid at position 778 is 
located at the beginning of the long helix (starting Thr761) 
in charge-rich environment – Glu, Asp, Arg. One can as-
sume that extensive solvation takes place in this region or 
that the region is important for its interaction dependent 
on Ca2+. Mutation of the Asp by Val not only changes the 
character of the interaction pattern with other amino acids 
or ions but Val, being a small hydrophobic amino acid, can 
completely change the stability of the region.
Short peptides mapping 769-788 amino acids region of 
myosin-7
The core idea behind the model of short peptides map-
ping 769-788 amino acids region was to localize the dif-
ferences in predicted peptide structures suggesting how 
the property of one amino acid can change the quality or 
the dynamics of the short sequence in question. As follows 
from the predicted structures, both regions are helical but 
there is one very important difference. The Asp778 is stabi-
lized by interaction with Arg777, and Glu779 is stabilized by 
interaction with Arg780 (Figure 2A). This introduces a ten-
sion in the helix and indeed, the predicted structure shows 
measurable difference from an ideal helicity. Contrary to 
Asp, the Val in position 778 does not destabilize the struc-
ture of the helix and seems to be an important stabilizing 
element of this part of the structure (Figure 2B). We do not 
have any information about dynamical behavior of this 
part of myosin-7, but dynamical behavior of both peptides 
is quite different. Short molecular dynamics simulation (10 
nanoseconds) in an explicit solvent revealed that rigidity of 
the Asp778Val mutant of the peptide was 5-6 times higher 
than of the Asp778 variant of the peptide.
diSCuSSion
We found Asp778Val alteration in exon 21 and the Arg870His 
in exon 22 of the MYH7 gene. These exons are mainly mu-
tated in cardiomyopathy patients and a presence of such 
Figure 1.
the homology model of myosin-7. Region of interest is highlighted.
Figure 2.
(A)the peptide spanning the region in which the mutation was located. aspartic acid makes salt bridge with the arginin and therefore introduces a ten-
sion into the presented helix. (B) if asp778Val mutation is present there is no deviation from the helicity during the simulation.MOLECULAR MEDICINE 388 Croat Med J. 2011; 52: 384-91
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a mutation is often considered to be linked with a very 
poor prognosis (25,26). Based on the results of the molecu-
lar genetic part of this study, a 3D model of myosin-7 was 
built. Structural prediction and functional analysis of mu-
tant and wild type variant of myosin-7 fragments showed 
the increased rigidity of the Asp778Val mutant affecting the 
dynamics and proper function of the myosin-7 protein. We 
hypothesize that it can change the dynamics and flexibil-
ity of the long helical part or it can modify its interaction 
property.
The 3D model of human myosin-7 was built using the x-ray 
structure of nucleotide-free scallop myosin S1 (1KK8) as the 
structural template. There are other models of human my-
osin-7 in databases – 1KK2 in PDB database and the model 
at Protein Model Portal (http://www.proteinmodelportal.
org/query/uniprot/P12883) based on the alignment of hu-
man myosin-7 with a sequence of Gallus gallus myosin, the 
structure of which was recently published (PDB ID 2MYS, 
sequence identity 79%). Structural alignment of our mod-
el with both obtained models showed similar root mean 
square deviation of about 14 Å. In both cases, the great-
est part of the difference is caused by distortion of the C-
terminal helix containing the studied mutations Asp778Val. 
Moreover, the part around residue 778 in 1KK2 model is 
significantly non helical, whereas both other models pro-
vide good agreement in this part.
All the patients from the cohort underwent the entry car-
diological and clinical examination and this provided the 
information about the disease severity in HCM patients. 
However,  long-term  follow-up  would  be  beneficial  to 
monitor the development of the HCM in patients with mu-
tations observed in this research.
In contrast to other studies, genetic results from this study 
show an unusually low number of mutations in the MYH7 
gene in the tested regions (14,27-29). Only Roncarati et al 
have recently reported a low frequency of mutations in the 
MYH7 gene in a large cohort of Italian patients with HCM 
(30). This indicates that there is a need for a more inclu-
sive investigative approach in order to fully understand the 
pathogenesis of this disease.
Mutation  location  in  the  MYH7  gene  and  the  resulting 
changes in amino acid composition may have a negative 
impact on the disease outcome in patients with HCM. Due 
to the different properties of the globular head domain 
(S1), neck or hinge domain (S2), and tail (light meromy-
osin) domain of the myosin-7 (31), mutations may 
have diverse effects depending on their location. In addi-
tion, as a mutation can give rise to a change in the amino 
acid sequence, the structure and interactive properties of 
the mutant protein may also be altered. Therefore, the po-
sitioning of the mutations along the gene and protein may 
offer insights into the mechanism by which normal protein 
function is impaired. It is hypothesized that a change in the 
amino acid charge may affect the severity of the pheno-
type (18).
The Arg870His substitution was first reported by Rayment et 
al. According to their research, defect of the Arg870His alter-
ation lies in the transmission of force to the thick filament 
array. This could affect the assembly of the thick filament or 
stability of the protein. If such defective myosin-7 proteins 
are present at the same levels as the wild type, the effect 
may be due to a loss of tensile strength or rigidity in this 
part of the molecule (31). According to Cuda et al, myo-
sin samples isolated from the soleus muscle tissue bearing 
the Arg870His mutation moved actin filaments more slowly 
than 22 control samples (32). It was reported that because 
both Arg and His residues are classified as basic amino acid 
residues, the nature of Arg870His mutation does not involve 
the change in charge (33). Nishi et al found that Arg870His 
mutation  might  not  cause  severe  clinical  manifestation 
in young persons (33). The possible defect of Arg870His is 
well documented and therefore we focused on the struc-
ture prediction and functional analysis of the 3D molecular 
model of myosin-7 (mutant “Asp778Val” and the wild type 
variant) in silico.
The Asp778Val alteration was first reported by Van Driest et 
al as a result of the comprehensive analysis of the MYH7 
gene in 389 unrelated patients with HCM in the USA (34). 
To our knowledge, no previous study performed 3D mo-
lecular modeling and a structure/function prediction of 
the wild type and mutant variant (Asp778Val) of myosin-7.
The mutation of the Asp by Val not only changes the 
character of the interaction pattern with other amino ac-
ids or ions but Val, being a small hydrophobic amino acid, 
can completely change the stability of the region. We hy-
pothesize that it can change the dynamics and flexibil-
ity of the long helical part or it can modify its interaction 
property. The Asp778Val amino acid alteration is situated 
in a region that is highly conserved inside of the known 
sequence of the myosin-7 protein, indicating that such 
a mutation may have a crucial structural and functional 
impact. As follows from the homology model and from 
the modeled peptides, there are at least two principal 389 Capek et al: Hypertrophic cardiomyopathy: from mutation to defective protein
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aspects that can possibly alter functionality of this do-
main dramatically. The first is the intramolecular stabiliza-
tion pattern dependent on Asp778 interaction with Arg777, 
which on the other hand can destabilize the helicity and 
make this part more dynamic. The second aspect is relat-
ed to the dynamics of the Asp778 and Asp778Val, which are 
different suggesting that Asp is important for proper flex-
ibility or probably the structure stability of myosin-7, and 
Val in this position increases rigidity, which seems to be 
counterproductive. Rigidity of the Asp778Val mutant can 
be very important factor in the dynamics of the myosin-7, 
together with other factors – Ca2+ affinity, EF hand-bind-
ing properties, and solvation of the region. This mutation 
may have negative impact on myosin, which generates 
less force and leads to the stimulus for compensatory hy-
pertrophy (35).
There are other two mutations that have been reported in 
the codon 778: 1. Asp778Gly (36) and Asp778Glu (37). If we 
follow our hypothesis that the flexibility of the region is 
the feature that influences the function, then the Asp778-
Glu should produce similar effect as the Val or Gly. All the 
amino acids – Val, Asp, and Glu (with the Gly as the only ex-
ception) have similar propensities for helical arrangement. 
Therefore, one CH2 longer side chain of the Glu can cre-
ate the salt bridge with the Arg777 without conformational 
stress, and therefore this mutation keeps the helix relatively 
untouched and similarly rigid as the Val or Gly.
In addition, a mutation that changes the charge of the 
amino acid is considered more likely to affect protein func-
tion than a conservative mutation as it was hypothesized 
by Ng and Henikoff (38). The role of charged residues can 
be divided into 4 major categories: a) creating a salt bridge 
bonds and stabilizing a structure; b) having a specific role 
in active sites of some enzymes; c) binding ions or metal 
atoms and coordinating their position in a structure; and 
d) increasing solubility of the protein and participating on 
protein-protein interactions. In the case of myosin-7, it is 
apparent that all categories except b) can take place. Syn-
ergy of all these effects could modify protein function sig-
nificantly more than if applied separately.
In conclusion, we found two mutations in the exons 21 
and 22 of the MYH7 gene in two unrelated patients with 
severe form of HCM with no family history of HCM. The As-
p778Val amino acid alteration was chosen for subsequent 
molecular modeling. For proper function of myosin-7, the 
Asp is important and Val in this position increases rigid-
ity, which seems to be counterproductive. This amino acid 
change may lead to the decreased contractility of myosin 
molecule.
The 3D molecular models and structure predictions of de-
fective proteins involved in the disease development fol-
lowed by functional analysis in silico could be essential in 
research on HCM in the very near future.
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